Recent Press Releases

Roche delivers solid sales growth for the first nine months of 2014

Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER1, stable in Swiss francs 4% higher sales in Pharmaceuticals Division, with strong growth of oncology...

Statement re: AbbVie's intention to reconsider recommendation

Statement re: AbbVie's intention to reconsider recommendation The Board of Shire plc (LSE: SHP, NASDAQ: SHPG) notes the announcement by AbbVie Inc. ("AbbVie") of its Board's...

Salinas Valley Memorial Healthcare System Boosts Broadband Speeds and Decreases Latency for Hundreds of Medical Practices and Facilities with Comcast Business Ethernet

New internet VPN system provides superior broadband support to help hospitals and physicians manage thousands of medical records across the county - especially those in rural and isolated location

Johnson & Johnson Reports 2014 Third-Quarter Results:

Sales of $18.5 Billion Increased 5.1% Versus 2013 Third Quarter;

NEW BRUNSWICK, N.J., Oct.

Johnson & Johnson Reports 2014 Third-Quarter Results

Sales of $18.5 Billion Increased 5.1% Versus 2013 Third Quarter; Third-Quarter EPS was $1.66 Excluding Special Items, 2014 Third-Quarter EPS of $1.50 Increased 10.3%* NEW BRUNSWICK, N.J., Oct. 14,...

Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market

Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market Gilead's Harvoni Might Be the Top Overall Performer, Says RxScorecard™, but a Discounted Triple Regimen From AbbVie...

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress HS is a...

SIRTURO® (bedaquiline) Wins UK Prix Galien Award for Most Innovative Orphan Drug

SIRTURO® (bedaquiline) Wins UK Prix Galien Award for Most Innovative Orphan Drug The first new medicine for tuberculosis in over 40 years has received the 2014 UK Prix Galien – regarded as...

FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy

FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and...

VEXIM to Initiate Clinical Study to Support Planned 510(k) Application to Market SpineJack® in the United States

VEXIM to Initiate Clinical Study to Support Planned 510(k) Application to Market SpineJack® in the United States

CEO

Regulatory News:

Abbott Celebrates the Power of Health and Achievement as First-Ever Title Sponsor of World Marathon Majors

SERIES WILL BE RENAMED ABBOTT WORLD MARATHON MAJORS STARTING IN 2015

ABBOTT PARK, Ill., Oct.

Hikma update on colchicine

Hikma update on colchicine London, 10 October 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group,...

Hikma update on colchicine

Hikma update on colchicine London, 10 October 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group,...

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA Company Receives Additional Paragraph IV Notice BETHESDA, Md., Oct. 9, 2014 (GLOBE NEWSWIRE) --...

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia Additional Global Regulatory Filings Reinforce Commitment to Addressing...

FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma

FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma This approval extends the benefit of VELCADE for mantle cell lymphoma (MCL) to...

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options

Impax To Acquire Tower Holdings, Inc. And Lineage Therapeutics Inc.

-- Acquisitions includes operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals LLC -- -- Provides Portfolio of Growing, High-Margin, Complex Generic and Branded Products -- -- Enhances...